NCT03093025终止2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Patients With Major Depressive Disorder With an Inadequate Response to Current Antidepressant Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 51
- 试验地点
- 22
- 主要终点
- Montgomery-Asberg Depression Rating Scale (MADRS)
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as an adjunctive treatment for patients with major depressive disorder with an inadequate response to current antidepressant Treatment (SSRI, SNRI or bupropion).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult males and females between 18 and 65 years of age inclusive (at time of initial informed consent)
- •Patients with a current diagnosis of MDD by DSM-5, confirmed through a structured interview using MINI
- •Patients who receive the same antidepressant (SSRI, SNRI or bupropion monotherapy) for at least 6 weeks of continuous treatment with at least 4 weeks on a fixed dose
- •Patients who willing to remain on the same primary SSRI, SNRI or bupropion and fixed dose throughout the course of the study
- •Patients who meet the total score on the HAM-D as listed below
- •HAM-D ≥ 18 at Screening
- •HAM-D ≥ 18 at Baseline
- •Body Mass Index (BMI) ≥ 18 and ≤ 38 kg/m2
排除标准
- •Patients with inadequate response to ≥2 prior antidepressant treatments (not including current antidepressant) of at least 4 weeks duration each for the current episode
- •Patients whose current depressive episode is diagnosed with psychotic features, catatonic features, post-partum (primary onset), or is secondary to a general medical disorder
- •Patients with a diagnosis of any of the following DSM-5 class disorders
- •Schizophrenia spectrum and other psychotic disorders
- •Bipolar and related disorders
- •Anxiety disorders [Co-morbid GAD and SAD will be allowed in the study if the primary diagnosis is MDD, and if in the opinion of the investigator, the comorbid anxiety is not likely to interfere with the subject's ability to participate in the trial or affect study outcome]
- •Obsessive-compulsive and related disorders
- •Trauma- and Stressor-related disorders
- •Patients who received electroconvulsive therapy (ECT) within 12 months of Screening, received more than one course of ECT in their lifetime or plan to receive ECT during the study
- •Patients who received repetitive transcranial magnetic stimulation (rTMS) within 12 months of Screening or plan to receive rTMS during the study
- •Patients who plan to initiate or terminate cognitive or behavioral psychotherapy or alter the frequency of ongoing therapy during this study
- •Patients who have attempted suicide within the past 6 months
- •Patients with history or presence of intellectual disability, pervasive developmental disorder, cognitive disorder, neurodegenerative disorder, or brain injury
- •Patients with any history or complication of convulsive disorder
- •Patients who are undergoing treatment with psychotropic medications, benzodiazepines, metyrapone, lithium and/or corticosteroids
- •Patients who are taking moderate to strong CYP3A4 inhibitors/inducers
研究组 & 干预措施
TS-121 10mg
Experimental
干预措施: TS-121 10 mg (Drug)
TS-121 50mg
Experimental
干预措施: TS-121 50 mg (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Montgomery-Asberg Depression Rating Scale (MADRS)
时间窗: 6 weeks
The MADRS is a clinician-rated scale to assess depressive symptoms which consists from 10 items. The time frame for this scale is the past 7 days. Each item is scored on 7-point scale (0 \[absence of symptoms\] to 6 \[severe\]). The total score is the sum of 10 items and can take range from 0 to 60. A negative change from baseline indicates improvement.
次要结局
- Hamilton Anxiety Scale (HAM-A)(6 weeks)
- Symptoms of Depression Questionnaire (SDQ)(6 weeks)
- Clinical Global Impression-Severity (CGI-S)(6 weeks)
- Montgomery-Asberg Depression Rating Scale (MADRS)(6 weeks)
- Clinical Global Impression-Improvement (CGI-I)(6 weeks)
研究者
研究点 (22)
Loading locations...
相似试验
已完成
2 期
An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT01022112Tanabe Pharma Corporation383
终止
1 期
Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT02134067Taiho Oncology, Inc.30
已完成
2 期
A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with NarcolepsyNarcolepsyNCT03267303Taisho Pharmaceutical Co., Ltd.53
终止
2 期
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.Major Depressive DisorderNCT01288079AstraZeneca145
已完成
3 期
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease PatientsParkinson's DiseaseNCT02337725Takeda244